You searched for "MET"
Results from the REDUCE study
Subjects in this paper were part of the Reduction by Dutasteride of PCa Events (REDUCE) study, a clinical trial enrolling men who had undergone a single negative prostate biopsy within six months of enrollment and subjecting them to a repeat...Join Prostate Cancer Research Free Webinar for Healthcare Professionals
Managing Sexual Side Effects After Prostate Cancer: A Patient & Therapist Perspective Date: 20 January 2026 — 6.00pm (London)Register: https://zoom.us/webinar/register/WN_CstOkvaUSNSg_xlFI1Z27w Why attend?Sexual side effects remain one of the most challenging and under-discussed consequences of prostate cancer treatment. This focused webinar...Male infertility
Definitions Infertility is the inability of a sexually active, non-contracepting couple to achieve spontaneous pregnancy in one year [1]. About 15% of couples do not achieve pregnancy within one year and seek medical treatment for infertility. Semen parameters are standardised...
Testosterone supplementation after prostatectomy – journey from bad to good
The role of androgens in the pathogenesis of prostate cancer is quite complex and is not entirely clear yet. Despite several reports suggesting testosterone use is safe in patients diagnosed with prostate cancer, many clinicians are still reluctant to use...
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...
MSKCC prostate cancer screening guidelines – is it the way forward?
The Memorial Sloan Kettering Cancer Center (MSKCC) developed prostate cancer screening recommendations first in 2011 as a response to three limitations of previous screening guidelines: insufficient evidence base, failure to link screening with treatment, and lack of risk stratification. To...
PDE5I in LUTS – how do they work – no proof yet
Phosphodiesterase type 5 (PDE5) inhibitors used in erectile dysfunction (ED) have been shown to improve lower urinary tract symptoms (LUTS) as well. The mechanism is not well understood. One of the hypotheses for benign prostatic hyperplasia (BPH) – LUTS is...
Can antibiotics reduce ‘unnecessary’ prostate biopsies?
With numerous factors capable of influencing prostate specific antigen (PSA) levels and therefore the likelihood of biopsy, this multi-centred randomised controlled trial (RCT) was designed to see if two weeks of ciprofloxacin compared to placebo would significantly reduce PSA levels...
